The reduction in the price target by Evercore ISI Group, while maintaining an In-Line rating, suggests a cautious outlook on the stock's short-term price movement. This adjustment reflects analyst Vijay Kumar's revised expectations for Edwards Lifesciences, potentially due to factors affecting the company's market position or financial performance. Investors may interpret the lowered price target as a signal of slower growth or increased risks, which could lead to a negative short-term impact on the stock price.